Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (allo-HCT) is the current recommended treatment. Professor Robin Foà (Sapienza University of Rome, Italy) joins us after the EBMT23 meeting to discuss his perspective on the ongoing debate of whether we should transplant all patients with Philadelphia Ph+ ALL. He explores the efficacy of some of the other options that are now available and the possibility of sparing patients from transplant.
Disclosures: Robin Foà has no financial or non-financial conflicts of interest to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Additional resources:
See more content on Leukaemia here
